Exact Sciences announced performance data for its blood-based colorectal cancer (CRC) screening test at the European Society of Medical Oncology (ESMO) Congress, the company announced recently. According to a release,…
Exact Sciences enrolled its first patient in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study, the company announced today. According to a release, the study will evaluate the…
Exact Sciences shared new modeling data that shows the impact of the Cologuard tests on patients, healthcare professionals and the U.S. healthcare system since its FDA approval a decade ago,…
Exact Sciences is collaborating with the Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients, the company announced recently. According to a release, the Mayo Clinic…
Exact Sciences has launched a hereditary cancer test in the United States called Riskguard, the company announced this week. According to a release, the test provides an individualized patient report…
Exact Sciences has awarded $1.3 million to 23 organizations through its Funding Opportunities for Colorectal Screening Uptake Strategies (FOCUS) Program, the company announced today. According to a release, the FOCUS…
Exact Sciences announced today that it acquired Resolution Bioscience from Agilent Technologies. According to a release, Resolution Bioscience’s blood-based diagnostic tests complement Exact Sciences’ Precision Oncology portfolio, providing a more…
Exact Sciences is partnering with two renowned healthcare organizations at the forefront of cancer research, the Broad Institute of MIT and Harvard along with Baylor Scott & White, the company…
Exact Sciences plans to submit next-generation Cologuard tests for FDA approval, the company announced recently. According to a release, the results from its BLUE-C study saw 94 percent sensitivity for…
Exact Sciences’ announced today its initial clinical validation data for its Profile for the Omission of Local Adjuvant Radiotherapy (POLAR). According to a release, POLAR is the first genomic signature…
